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Abstract 
Introduction: In 2008, the Federal Drug Administration (FDA) required all new glucose-lowering 
therapies to show cardiovascular safety, and this applies to the dipeptidyl peptidase (DPP)-4 
inhibitors (‘gliptins’).  At present, there is contradictory evidence on whether the gliptins increase 
hospitalizations for heart failure. 
Areas covered: This is an evaluation of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin 
(TECOS) in high risk cardiovascular subjects with type 2 diabetes [1]. TECOS demonstrated non-
inferiority for sitagliptin over placebo for the primary outcome, which was cardiovascular death, 
nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina.  There was no 
difference in the rate of hospitalization for heart failure between sitagliptin and placebo.  
Expert Opinion: Despite the results of TECOS, debate over the effects of sitagliptin on the rates of 
hospitalizations for heart failure continues with some recent studies suggesting increased rates.  
Recently, empagliflozin (an inhibitor of sodium-glucose cotransporter 2) has been shown to reduce 
cardiovascular outcomes in subjects with type 2 diabetes, including the rates of hospitalization for 
heart failure.  In our opinion, these positive findings with empagliflozin suggest that it should be 
prescribed in preference to the gliptins, including sitagliptin, unless any positive cardiovascular 
outcomes are reported for the gliptins.  
 
Key words: cardiovascular benefit, cardiovascular risk, clinical trials, empagliflozin, heart failure, 
sitagliptin, type 2 diabetes 
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1. Introduction 
The dipeptidyl peptidase (DPP)-4 inhibitors (the ‘gliptins’) are a relatively new group of medicines for 
the treatment of diabetes.  These agents inhibit the degradation of the incretin hormones (e.g. 
glucagon-like peptide-1; GLP-1), leading to the increased levels of these hormones.  GLP-1 stimulates 
insulin secretion, with the reduction of HbA1c levels in subjects with type 2 diabetes.  The DPP-4 
inhibitor sitagliptin was approved in 2006 by the FDA.  Subsequent to this vilagliptin, saxagliptin, 
alogliptin and linagliptin have also been approved.   
In the light of increased cardiovascular events reported with glitazones, since 2008, the US FDA, and 
from 2010, the European Medicines Agency (EMA) have required that all new glucose-lowering 
therapies, as a minimum, be required to show cardiovascular safety, even if there is no benefit.  
Cardiovascular outcomes trials with saxagliptin and alogliptin have already been reported; the 
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-
Thrombolysis in Myocardial Infarction (TIMI) 53 trial [2], and with alogliptin; Examination of 
Cardiovascular Outcomes with Alogliptin versus Standard of Care; EXAMINE [3].  These trials showed 
that saxagliptin and alogliptin did not increase the primary endpoint, which was a composite of 
cardiovascular outcomes that did not include hospitalizations for heart failure.  However, saxagliptin 
significantly increased hospitalization for heart failure, which was a component of the secondary 
endpoint [3].  The effect of alogliptin on hospitalizations for heart failure had not been reported at 
this time.  Subsequently, the data from EXAMINE has been used to show that risk of hospital 
admission for heart failure occurring as the first event was similar for alogliptin and placebo, as was 
the composite endpoint of cardiovascular death and hospital admission for heart failure, and this 
was independent of whether subjects had heart failure or not at baseline [4].  However, in subjects 
with a history of heart failure, alogliptin did increase hospitalizations for heart failure [4].   
The cardiovascular safety outcomes trial for sitagliptin has recently been published; Trial Evaluating 
Cardiovascular Outcomes with Sitagliptin (TECOS) [1].  In our evaluation of sitagliptin in TECOS, 
special attention is given to the relationship with the use of sitagliptin and heart failure.  There is no 
evidence of an increased rate of hospitalizations for heart failure with sitagliptin in TECOS. 
2. Sitagliptin in TECOS 
A summary of the methods and results of TECOS [1] are given in this section.  TECOS was a 
randomised, double-blind clinical trial run at 673 sites in 38 countries.  To be enrolled, subjects with 
type 2 diabetes had to have established cardiovascular disease; major coronary artery disease, 
ischemic cerebrovascular disease, or atherosclerotic peripheral arterial disease.  Subjects had to be 
at least 50 years old, with an HbA1c of 6.5-8.0%, despite treatment with one or two of metformin, a 
sulfonylurea, or pioglitazone or insulin with or without metformin.  Subjects that were excluded 
included those who had experienced severe hypoglycaemia or had an estimated glomerular 
filtration rate of less than 30 ml/min/1.73 m2. 
TECOS had 14671 subjects in the intention-to-treat population with a mean HbA1c of 7.2%, who had 
a mean age of ~66 years, and 68% were White (22% Asian).  Seventy-four percent had prior 
cardiovascular disease, 25% prior cerebrovascular disease, and 18% prior congestive heart failure.  
Eighty-two percent were taking metformin, 45% a sulfonylurea, 3% pioglitazone and 23% insulin.  
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Subjects were randomised to sitagliptin 100 mg (or 50 mg, if they had reduced kidney function) or 
placebo.  After 4 months, the HbA1c was 0.4% lower in the sitagliptin group than the placebo group.  
During the study, the addition of open-label medicines to reduce HbA1c towards acceptable norms 
was allowed.  As a consequence of this, during the study, more subjects in the placebo group than 
the sitagliptin group initiated insulin (13.2% vs 9.7%) and had additional antihyperglycemic agents 
(27.9% vs 21.7%).  At the end of the study, the HbA1c was 0.29% lower in the sitagliptin than 
placebo group. 
The study was continued until 1300 subjects had the primary composite outcome, which was 
cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable 
angina.  This composite occurred in 839 of 7332 subjects in the sitagliptin group (11.4%), compared 
to 851 of 7339 subjects in the placebo group (11.6%), which demonstrated non-inferiority for 
sitagliptin over placebo. 
Of the secondary outcomes, there was no difference in the rate of hospitalization for heart failure 
between the sitagliptin group (228 subjects, 3.1%) and the placebo group (229 subjects, 3.1%).  
There were also no differences between sitagliptin and placebo for the composite of hospitalization 
for heart failure and cardiovascular death, or for death from any cause alone. 
Subgroup analysis showed that sitagliptin was better than placebo for the primary composite 
outcome in those with a body mass index ≥ 30 kg/m2 than for those subjects < 30 kg/m2.  For all 
other subgroups (e.g. diabetes therapy, diabetes duration, HbA1c, prior congestive heart failure), 
there was no difference between sitagliptin and placebo, within the subgroup. 
The percentage of subjects who discontinued the drug was similar for the sitagliptin and placebo 
groups (4.9% vs 5.9%).  During the trial, the overall incidence of infections, cancer, and site-reported 
renal failure was similar for both groups.  Although the incidence of acute pancreatic events or 
pancreatic cancers was not significantly different between sitagliptin and placebo, the numbers were 
higher for pancreatic events (sitagliptin 23, 0.3%; placebo 12, 0.2%) and lower for pancreatic cancers 
(sitagliptin 9, 0.1%; placebo 14, 0.2%). 
3. Expert opinion 
 
3.1 Sitagliptin and heart failure clinically and experimentally 
Although, clinically, TECOS suggests than sitagliptin does not increase the incidence of 
hospitalizations for heart failure, two other recent studies suggest that sitagliptin increases the 
incidence of this hospitalization in subjects with type 2 diabetes.  Thus, in a population-based study 
of 8288 matched pairs from Taiwan, 7% with pre-existing heart failure, the first event of 
hospitalization for heart failure over 1.5 years, occurred in 339 subjects treated with sitagliptin, 
compared to 275 subjects not treated [5].  Similarly, from a large US insurance claims database, it 
was also shown that sitagliptin increased heart failure related hospitalizations in subjects with 
diabetes and pre-existing heart failure [6].  In contrast, a Taiwanese study of subjects with diabetes, 
chronic kidney disease and acute myocardial infarction, sitagliptin did not increase hospitalizations 
for heart failure, but did increase the risk of recurrent myocardial infarction and percutaneous 
coronary revascularization [7].   
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The gliptins are not selective inhibitors of the incretin hormones, as DPP-4 metabolises many 
biologically active peptides including neuropeptide Y (NPY) 1-36 (released from cardiac sympathetic 
nerve) and the circulating peptide YY (PYY) 1-36.  These peptides stimulate the Y1 receptor to 
increase blood pressure and the number of cardiac fibroblasts.  Inhibiting the metabolism of NPY 1-
36 PYY 1-36 with sitagliptin, in rat models of hypertension and diabetes, has been shown to increase 
hypertension and cardiac fibroblast numbers, and it has been postulated that this may be the 
mechanisms underlying the effects of gliptins in subjects with heart failure [8,9]. 
Thus, it seems to us, that the clinical safety testing with sitagliptin needs to be ongoing until there is 
a clear cut result on the safety, or not, of sitagliptin in subjects with cardiovascular disease.  
Experimentally studies to elucidate mechanisms of sitagliptin that may be detrimental should also be 
continued. 
3.2 Change in diabetic medications/HbA1c during study 
In TECOS, the use of anti-diabetic medicines was matched at baseline [1].  However, there was an 
increased use of insulin and other antihyperglycemic agents in the placebo group during the study, 
such that the anti-diabetic medications were no longer matched at the end of the study [1].  The 
increased use of anti-diabetic medications in the placebo group, was probably responsible for the 
small difference in HbA1c between the sitagliptin and placebo group in TECOS; 0.29%.  As a 1% 
reduction in HbA1c was shown to be necessary for a reduction of 14-37% in cardiovascular outcomes 
in subjects with type 2 diabetes in UKPDS 35 [10], we are not sure whether a reduction of 0.29% will 
ever be enough to improve cardiovascular outcomes.  
3.3 Microvascular disease 
Microvascular disease (retinopathy, neuropathy, and nephropathy) was not evaluated in TECOS, 
despite being a major consequence of diabetes.  Indeed, subjects with evidence of kidney disease 
were excluded from TECOS.  Although there were no reports of renal failure with sitagliptin in 
TECOS, it should be noted that 79% of the subjects were taking a blocker of the renin-angiotensin-
aldosterone system throughout [1], and these would have offered nephroprotection.  As 
improvements in microvascular disease are important requirements in diabetes, the effects of 
sitagliptin on these needs to be evaluated. 
3.4 Gliptins vs sulfonylureas 
The gliptins are often preferred to the oral sulfonylureas in the treatment of type 2 diabetes as, 
unlike the sulfonylureas, they do not cause weight gain, and the incidence of hypoglycaemia is lower 
with the gliptins than with the sulfonylureas.  There is also recent evidence that the use of a gliptin-
metformin combination is associated with decreased risks of major cardiovascular events, compared 
to a sulfonylurea-metformin combination [11].    However, rather that indicating a benefit of the 
gliptins over the sulfonylureas, this may indicate that sulfonylureas have detrimental effects on 
cardiovascular events, especially as there is growing evidence that this is the case [e.g. 12].  This 
suggests to us that the sulfonylureas should not be used in the treatment of diabetes, and thus, we 
do not need an alternative.  Rather, we need drugs to treat diabetes that improve cardiovascular 
outcomes in their own right. 
3.5 Cardiovascular outcomes with gliptins 
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In our previous evaluation of saxagliptin and alogliptin we concluded “Neither agent improved 
cardiovascular outcomes.  Whilst there is no published evidence of improved outcomes with gliptins, 
it is unclear to us why these agents are so widely available for use.  We suggest that the use of 
gliptins be restricted to Phase IV clinical trials until such time as cardiovascular safety and 
benefits/superiority are clearly established” [13].  As sitagliptin, saxagliptin, alogliptin alone in 
cardiovascular safety outcome trials [1,2,3,4] or combined gliptins in meta-analysis [14]  have not 
been shown to improve cardiovascular outcomes, our conclusion has not changed. 
3.6 Inhibitors of the sodium-glucose cotransporter 2 (SGLT2) 
The gliptins are in competition with the SGLT2 inhibitors for use in combination with metformin in 
the treatment of type 2 diabetes.  Recently, one of the SGLT2 inhibitors, empagliflozin, has been 
shown to reduce the primary composite outcome of death from cardiovascular causes, nonfatal 
myocardial infarction, or nonfatal stroke in subjects with type 2 diabetes, at high risk of 
cardiovascular events, compared to placebo [15].  Empagliflozin also reduced the risk of 
hospitalisations for heart failure [15].   Given the favourable cardiovascular outcomes profile with 
empagliflozin over sitagliptin, it is our opinion that empagliflozin should be prescribed in preference 
to the gliptins in subjects with type 2 diabetes at high risk of cardiovascular events, unless any 
positive cardiovascular outcomes are reported for the gliptins. 
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